Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia
Conclusion: Our data show that AZA monotherapy is safe and effective in controlling disease both in upfront and relapsed patients in order to proceed to HSCT.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Children | Genetics | Hematology | Hepatomegaly | Leukemia | Myeloproliferative Disorders | Pediatrics | Romania Health | Stem Cell Therapy | Stem Cells | Study | Transplants